The Association of Human Papillomavirus Type 16 E6 and E7 Antibodies with Stage of Cervical Cancer

Demographic and risk factors in patients with head and neck tumors

“…Antibodies to HR HPV oncoproteins E6 and E7 are rarely present in healthy individuals but are very often detected in cases with cancers etiologically linked with HPV. Several studies reported that prevalence of anti-E6/E7 antibodies decreases after successful treatment [Fisher et al, 1996;Di Lonardo et al, 1998;Baay et al, 1999;Hamsiková et al, 2000;Zumbach et al, 2000;Silins et al, 2002;Ravaggi et al, 2006;Smith et al, 2007]. Cases and healthy subjects also differed in this study in their immunological characteristics.…”

Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia

“…Although data exist for few cases only, an increase with stage is apparent also for HPV18 E6 and/or E7 antibodies. For HPV16 antibodies, a similar dependence was found by RIPA using HPV16 E6 and E7 antigens (Chee et al, 1995), whereas in 2 other studies (Fisher et al, 1996;Park et al, 1998) statistically significant stage dependence was found only for E7 but not for E6. With HPV16-E7 peptide ELISA the prevalence of antibodies also tended to increase by tumor stage (Baay et al, 1995;Gaarenstroom et al, 1994).…”

“…Interestingly, a slight preponderance, ranging from 1.2 to 1.8, of HPV16 E6 antibodies over E7 antibodies has been seen in other studies that used RIPA (Viscidi et al, 1993;Fisher et al, 1996;Sun et al, 1994;Park et al, 1998;Chee et al, 1995), except for Baay et al (1999) where an equal distribution was shown. In studies using peptide ELISA with 0.4 and 0.5 the opposite ratio was observed (Müller et al, 1992;Fisher et al, 1996).…”

“…Interestingly, a slight preponderance, ranging from 1.2 to 1.8, of HPV16 E6 antibodies over E7 antibodies has been seen in other studies that used RIPA (Viscidi et al, 1993;Fisher et al, 1996;Sun et al, 1994;Park et al, 1998;Chee et al, 1995), except for Baay et al (1999) where an equal distribution was shown. In studies using peptide ELISA with 0.4 and 0.5 the opposite ratio was observed (Müller et al, 1992;Fisher et al, 1996). Since the preponderance of E6 antibodies has been seen independently in different studies and with 2 different types of assays (RIPA and ELISA with whole, re-natured proteins), we speculate that this difference, rather than reflecting mere differences in sensitivity of antibody detection, indicates higher protein levels of E6 or increased immunogenicity in comparison to E7.…”

Epidemiology: A Tool for the Study of Human Papillomavirus-Related Carcinogenesis

“…A recent preliminary report of 137 women diagnosed with cervical cancer suggested that an HPV-specific humoral immune response may increase with the cervical cancer stage and decrease following tumor therapy [73], Very little data are available regard ing cell-mediated responses with HPV infection. Cellmediated immunity among patients with epidermodysplacia verruciformis is characterized by decreased cyto toxicity and decreased T helper cells [74,75].…”